EU Advisory Panel Clears Sanofi’s Jevtana But Wants to Review Multaq’s Liver Risks

Sanofi-Aventis' cabazitaxel receives a positive opinion from the EU's scientific advisory committee, but the benefit/risk balance of the French company's anti-arrhythmic, Multaq, needs to be reviewed.